Tumour vascular targeting

Nature Reviews Cancer

Volumn 5, Issue 6, 2005, Pages 436-446

  Neri, Dario ^a   Bicknell, Roy ^b  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; FIBRONECTIN; INTEGRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; TENASCIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BIOINFORMATICS; DNA MICROARRAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; LIGANDS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 20344367537     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1627     Document Type: Review

References (159)

1. Konerding, M. A., Fait, E. & Gaumann, A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br. J. Cancer 84, 1354-1362 (2001).
2. Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393 (2000).
3. McDonald, D. M. & Choyke, P. L. Imaging of angiogenesis: from microscope to clinic. Nature Med 9, 713-725 (2003). A comprehensive review of the tumour vasculature and ways to image it.
4. Tozer, G. M. et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv. Drug Deliv. Rev. 57, 135-152 (2005).
5. Tozer, G. M., Lewis, S., Michalowski, A. & Aber, V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br. J. Cancer 61, 250-257 (1990).
6. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature Med. 3, 177-182 (1997).
7. Denekamp, J. & Hobson, B. Endothelial-cell proliferation in experimental tumours. Br. J. Cancer 46, 711-720 (1982).
8. Brown, N. S. & Bicknell, R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3, 323-327 (2001).
9. Toyokuni, S., Okamoto, K., Yodoi, J. & Hiai, H. Persistent oxidative stress in cancer. FEBS Lett. 358, 1-3 (1995).
10. Mailhos, C. et al. Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 89, 135-144 (2001).
11. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9, 267-282 (1990).
12. Woglom, W. A critique of tumor resistance. J. Cancer Res. 7, 283-309 (1923).
13. Burrows, F. J. & Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl Acad. Sci. USA 90, 8996-9000 (1993). The first proof that targeted anti-vascular therapy can eradicate solid tumours.
14. Huang, X. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550 (1997).
15. Clarke, M. S. & West, D. C. The identification of proliferation and tumour-induced proteins in human endothelial cells: a possible target for tumour therapy. Electrophoresis 12, 500-508 (1991).
16. Adams, M. D. et al. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature 377, 3-174 (1995).
17. Parker, L. H. et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 426, 754-758 (2004).
18. Huminiecki, L. & Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res. 10, 1796-1806 (2000).
19. Huminiecki, L., Gorn, M., Suchting, S., Poulsom, R. & Bicknell, R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79, 547-552 (2002).
20. Sullivan, D. C. et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J. Biol. Chem. 278, 47079-47088 (2003).
21. Park, K. W. et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev. Biol. 261, 251-267 (2003).
22. Ho, M, et al. Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol. Genomes 13, 249-262 (2003).
23. Hidai, C. et al. Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the αvβ3 integrin receptor. Genes Dev. 12, 21-33 (1998).
24. Gerritsen, M. E. et al. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol. Genomics 10, 13-20 (2002).
25. Kahn, J. et al. Gene expression profiling in an in vitro model of angiogenesis. Am. J. Pathol. 156, 1887-1900 (2000).
26. Zlot, C. et al. Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. J. Biol. Chem. 278, 47654-47659 (2003).
27. St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000). The identification of tumour endothelial markers by isolation of endothelium from normal and tumour tissue followed by construction of SAGE libraries and a comparison of gene expression.
28. Carson-Walter, E. B. et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61, 6649-6655 (2001).
29. Nanda, A. & St Croix, B. Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 16, 44-49 (2004).
30. Bjarnadottir, T. K. et al. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. Genomics 84, 23-33 (2004).
31. Walter-Yohriing, J. et al. Murine endothelial cell lines as models of tumor endothelial cells. Clin. Cancer Res. 10, 2179-2189 (2004).
32. Christian, S. et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J. Biol. Chem. 276, 7408-7414 (2001).
33. Rettig, W. J. et al. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl Acad. Sci. USA 89, 10832-10836 (1992).
34. MacFadyen, J. R. et al. Endosialin (TEM1, CD284) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 570, 2569-2575 (2005).
35. Duesbery, N. S. et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc. Natl Acad. Sci. USA 98, 4089-4094 (2001).
36. Shutter, J. R. et al. DII4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 14, 1313-1318 (2000).
37. Rao, P. K. et al. Isolation and characterization of the Notch ligand Delta4. Exp. Cell Res. 260, 379-386 (2000).
38. Liu, Z. J. et al. Regulation of Notch1 and DII4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol. Cell Biol. 23, 14-25 (2003).
39. Morgan, S. M., Samulowitz, U., Darley, L., Simmons, D. L. & Vestweber, D. Biochemical characterization and molecular cloning of a novel endothelial-specific sialomucin. Blood 93, 165-175 (1999).
40. Liu, C. et al. Human endomucin is an endothelial marker. Biochem. Biophys. Res. Commun. 288, 129-136 (2001).
41. Scheurer, S. B., Raybak, J. N., Rosli, C., Neri, D. & Elia, G. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: a transcriptomic and proteomic study. Proteomics 4, 1737-1760 (2004).
42. Jacobsen, L. et al. Molecular characterization of a novel human hybrid-type receptor that binds the α2- macroglobulin receptor-associated protein. J. Biol. Chem. 271, 31379-31383 (1996).
43. Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629-635 (2004). A comprehensive proteomic analysis identifying tumour endothelial markers.
44. Matsubara, S., Bourdeau, A., terBrugge, K. G., Wallace, C. & Letarte, M. Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke 31, 2653-2660 (2000).
45. Christian, S. et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163, 871-878 (2003).
46. Rybak, J. N. et al. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nature Methods 23, 291-298 (2005).
47. Stanford, W. L. et al. Expression trapping: identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. Blood 92, 4622-4631 (1998).
48. Hirashima, M., Bernstein, A., Stanford, W. L. & Rossant, J. Gene-trap expression screening to identify endothelial-specific genes. Blood 104, 711-718 (2004).
49. Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337-2342 (1987).
50. Carnemolla, B. et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108, 1139-1148 (1989).
51. Kaczmarek, J. et al. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 59, 11-16(1994).
52. Castellani, P. et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612-618 (1994).
53. Carnemolla, B. et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68, 397-405 (1996).
54. Castellani, P. et al. Differentiation between high- and low- grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161, 1695-1700 (2002). The article convincingly demonstrates that EDB is a marker of angiogenesis for brain tumours, and suggests innovative approaches for the differential diagnosis of high-grade and low-grade astrocytomas.
55. Katenkamp, K. et al. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J. Pathol. 203, 771-779 (2004).
56. Hauptmann, S. et al. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab. Invest. 73, 172-182 (1995).
57. Birchler, M. T. et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 113, 1231-1237 (2003).
58. Vogel, W. et al. Differential in vivo and in vitro expression of ED-B+ fibronectin in adult human hematopoiesis. Int. J. Mol. Med. 12, 831-837 (2003).
59. Peters, J. H., Chen, G. E. & Hynes, R. O. Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes. Commun. 4, 127-148 (1996).
60. Peters, J. H. & Hynes, R. O. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell Adhes. Commun. 4, 103-125 (1996).
61. Carnemolla, B., Leprini, A., Allemanni, G., Saginati, M. & Zardi, L. The inclusion of the type III repeat ED-B in the fibronectin molecule generates confomnational modifications that unmask a cryptic sequence. J. Biol. Chem. 267, 24689-24692 (1992).
62. Giovannoni, L., Viti, F., Zardi, L. & Neri, D. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res. 29, E27 (2001).
63. Neri, D. et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol. 15, 1271-1275 (1997).
64. Pini, A. et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769-21776 (1998).
65. Viti, F., Tarli, L., Giovannoni, L., Zardi, L. & Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347-352 (1999).
66. Tarli, L. et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 94, 192-198 (1999).
67. Demartis, S., Tarli, L., Borsi, L., Zardi, L. & Neri, D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med. 26, 534-539 (2001).
68. Borsi, L. et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75-85 (2002).
69. Santimaria, M. et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9, 571-579 (2003).
70. Fattorusso, R. et al. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Structure Fold. Des. 7, 381-390 (1999).
71. Fukuda, T. et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 82, 5603-5610 (2002).
72. Birchler, M. et al. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J. Immunol. Methods 231, 239-248 (1999).
73. Birchler, M., Viti, F, Zardi, L., Spiess, B. & Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nature Biotechnol. 17, 984-988 (1999).
74. Marly, C. et al. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer 87, 106-112 (2002).
75. Nilsson, F., Kosmehl, H., Zardi, L. & Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 61, 711-716 (2001).
76. Carnemolla, B. et al. Enhancement of the antitumor properties of interteukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659-1665 (2002).
77. Halin, C., Niesner, U., Villani, M. E., Zardi, L. & Neri, D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer 102, 109-116 (2002).
78. Halin, C. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nature Biotechnol. 20, 264-269 (2002).
79. Borsi, L. et al. Selective targeted delivery of TNFα to tumor blood vessels. Blood 102, 4384-4392 (2003).
80. Heinis, C., Alessi, P. & Neri, D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry 43, 6293-6303 (2004).
81. Melkko, S., Halin, C., Borsi, L., Zardi, L. & Neri, D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int. J. Radiat. Oncol. Biol. Phys. 54, 1485-1490 (2002).
82. Niesner, U. et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug. Chem. 13, 729-736 (2002).
83. Borsi, L. et al. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 52, 688-692 (1992).
84. Carnemolla, B. et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am. J. Pathol. 154, 1345-1352 (1999).
85. Riva, P. et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin. Cancer Res. 5, 3275s-3280s (1999).
86. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma: phase I and II study. Acta Oncol. 38, 351-359 (1999).
87. Paganelli, G. et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26, 348-357 (1999). An ingenious pre-targeting approach leads to an impressive selectivity for trie targeting of gliomas with radiolabelled compounds and validates oncofetal tenascin-C as an attractive target antigen.
88. 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 104, 642-648 (2004).
89. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389-1397 (2002).
90. Friedlander, M. et al. Definition of two angiogenic pathways by distinct αv integrins. Science 270, 1500-1502 (1995).
91. Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407 (2002).
92. 3. Clin. Cancer Res. 6, 3056-3061 (2000).
93. 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. 16, 125-132 (2001).
94. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. & McDonald, D. M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163, 1801-1815 (2003).
95. 3-targeted magnetic resonance imaging. Nature Med. 4, 623-626 (1998).
96. Pasqualini, R., Koivunen, E. & Ruoslahti, E. αv integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnol. 15, 542-546 (1997).
97. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146-6151 (2002).
98. 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350-359 (2004).
99. Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391-400 (2004).
100. Carmeliet, P. Angiogenesis in health and disease. Nature Med. 9, 653-660 (2003).
101. He, Y., Karpanen, T. & Alitalo, K. Role of lymphangiogenic factors in tumor metastasis. Biochim. Biophys. Acta 1654, 3-12 (2004).
102. Streit, M. & Detmar, M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22, 3172-3179 (2003).
103. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004).
104. Brekken, R. A., Huang, X., King, S. W. & Thorpe, P. E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58, 1952-1959 (1998).
105. Cooke, S. P. et al. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res. 61, 3663-3659 (2001).
106. Ke, L. et al. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur. J. Cancer 32A, 2467-2473 (1996).
107. Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209-5218 (1999).
108. Zhu, Z. & Witte, L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs 17, 195-212(1999).
109. Brekken, R. A. et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60, 5117-5124 (2000).
110. Bostwick, D. G. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124, 995-1000 (2000).
111. Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198 (1999).
112. Liu, H. et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57, 3629-3634 (1997). PSMA is shown to be an attractive marker of angiogenesis for antibody-based targeting approaches.
113. Bander, N. H. et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 30, 667-676 (2003).
114. Milowsky, M. I. et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531 (2004).
115. Li, Y, Tian, Z., Rizvi, S. M., Bander, N. H. & Allen, B. J. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 5, 36-46 (2002).
116. 211 At. Radiat. Res. 157, 633-641 (2002).
117. Wang, J. M. et al. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 54, 363-370 (1993).
118. Burrows, F. J. et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1, 1623-1634 (1995).
119. Balza, E. et al. Lack of specificity of endoglin expression for tumor blood vessels. Int. J. Cancer 94, 579-585 (2001).
120. Bredow, S., Lewin, M., Hofmann, B., Marecos, E. & Weissleder, R. Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Eur. J. Cancer 38, 675-681 (2000).
121. Fonsatti, E. et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res. 6, 2037-2043 (2000).
122. Wakai, Y. et al. Effective cancer targeting using an antitumor tissue vascular endothelium-specific monoclonal antibody (TES-23). Jpn. J. Cancer Res. 91, 1319-1325 (2000).
123. 186Relabeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 9, 3961S-3972S (2003).
124. Verel, I. et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer 99, 396-402 (2002).
125. Pasqualini, R. et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722-727 (2000).
126. Curnis, F. et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nature Biotechnol. 18, 1185-1190 (2000). A tumour-homing peptide, previously identified by in vivo peptide phage panning procedures, can be appended to TNF and increases the anticancer therapeutic index of this pro-inflammatory cytokine.
127. Curnis, F., Sacchi, A. & Corti, A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110, 475-482 (2002).
128. Weller, G. E. et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res. 65, 533-539 (2005).
129. Ran, S., Downes, A. & Thorpe, P. E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62, 6132-6140 (2002).
130. Bucki, R., Janmey, P. A., Vegners, R., Giraud, F. Sulpice, J. C. Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide. Biochemistry 40, 15752-15761 (2001).
131. 3 integrin. Cancer Cell 3, 589-601 (2003).
132. Bello, L. et al. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clin. Cancer Res. 10, 4527-4537 (2004).
133. Adams, G. P. et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750-4755 (2001). This important article shows how low doses of high affinity antibodies specific to a tumour-cell marker tend to accumulate in the perivascular area of solid tumours.
134. Schmitt-Sody, M. et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 9, 2335-2341 (2003).
135. Li, Y. et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med 195, 1575-1584 (2002).
136. Niederman, T. M. et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl Acad. Sci. USA 99, 7009-7014 (2002).
137. Reisfeld, R. A., Niethammer, A. G., Luo, Y. & Xiang, R. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol. Rev. 199, 181-190 (2004).
138. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
139. Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455 (1994).
140. Schaffitzel, C., Hanes, J., Jermutus, L. & Pluckthun, A. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Methods 231, 119-135 (1999).
141. Graff, C. P., Chester, K., Begent, R. & Wittrup, K. D. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C. Protein Eng. Des. Sel. 17, 293-304 (2004).
142. Olafsen, T. et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng. Des. Sel. 17, 315-323 (2004).
143. Scott, J. K. & Smith, G. P. Searching for peptide ligands with an epitope library. Science 249, 386-390 (1990).
144. Felici, F. et al. Peptide and protein display on the surface of filamentous bacteriophage. Biotechnol. Annu. Rev. 1, 149-183 (1995).
145. Collins, J., Horn, N., Wadenback, J. & Szardenings, M. Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol. 74, 317-338 (2001).
146. Frank, R. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports -principles and applications. J. Immunol. Methods 267, 13-26 (2002).
147. Pinilla, C., Appel, J. R., Borras, E. & Houghten, R. A. Advances in the use of synthetic combinatorial chemistry: mixture-based libraries. Nature Med. 9, 118-122 (2003).
148. Terskikh, A. V. et al. "Peptabody": a new type of high avidity binding protein. Proc. Natl Acad. Sci. USA 94, 1663-1668 (1997).
149. Wrighton, N. C. et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nature Biotechnol. 15, 1261-1265 (1997).
150. Ellington, A. D. & Szostak, J. W. Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nafure 355, 850-652 (1992).
151. Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M. & Gold, L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl Acad. Sci. USA 100, 15416-15421 (2003).
152. Helmling, S. et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc. Natl Acad. Sci. USA 101, 13174-13179 (2004).
153. Beck-Sickinger, A. & Weber, P. Combinational Strategies in Biology and Chemistry (John Wiley & Sons, Chichester, Sussex, 2001).
154. Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
155. Melkko, S., Scheuermann, J., Dumelin, C. E. & Neri, D. Encoded self-assembling chemical libraries. Nature Biotechnol. 22, 568-574 (2004).
156. Gartner, Z. J. et al. DNA-templated organic synthesis and selection of a library of macrocycles. Science 305, 1601-1605 (2004).
157. Ramstrom, O. & Lehn, J. M. Drug discovery by dynamic combinatorial libraries. Nature Rev. Drug Discov. 1, 26-36 (2002).
158. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Discov. 3, 301-317 (2004).
159. Muckenschnabel, I., Falchetto, R., Mayr, L. M. & Filipuzzi, I. SpeedScreen: label-free liquid chromatography-mass speotrometry-based high-throughput screening for the discovery of orphan protein ligands. Anal. Biochem. 324, 241-249 (2004).